Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: A randomised controlled trial

Respiratory Research

Volumn 14, Issue 1, 2013, Pages

  Berkhof, Farida F ^a   Hertog, Nynke E D ^a   Uil, Steven M ^a   Kerstjens, Huib A M ^b   van den Berg, Jan W K ^a  

^a Department of pulmonary diseases Isala ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Azithromycin; COPD; Cough; Health status; LCQ

Indexed keywords

AZITHROMYCIN; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHEMOPROPHYLAXIS; CHRONIC COUGH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMON COLD; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICATION COMPLIANCE; MICROBIOLOGICAL PARAMETERS; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STOMACH ULCER; SUPRAVENTRICULAR TACHYCARDIA; TASTE DISORDER; TREATMENT OUTCOME; CHRONIC DISEASE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SPIROMETRY;

AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHRONIC DISEASE; COMORBIDITY; COUGH; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; SPIROMETRY; TREATMENT OUTCOME;

EID: 84887380301     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-14-125     Document Type: Article

References (36)

1. Mathers CD, Boerma T, Ma FD. Global and regional causes of death. Br Med Bull 2009, 92:7-32. 10.1093/bmb/ldp028, 19776034.
2. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-750. 10.1016/S0140-6736(07)61377-4, 17765523.
3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van WC, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555. 10.1164/rccm.200703-456SO, 17507545.
4. de MR, Accordini S, Cerveri I, Corsico A, Anto JM, Kunzli N, Janson C, Sunyer J, Jarvis D, Chinn S, Vermeire P, Svanes C, ckermann-Liebrich U, Gislason T, Heinrich J, Leynaert B, Neukirch F, Schouten JP, Wjst M, Burney P. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007, 175:32-39. 10.1164/rccm.200603-381OC, 17008642.
5. Martinez-Garcia MA, Soler-Cataluna JJ, Donat SY, Catalan SP, Agramunt LM, Ballestin VJ, Perpina-Tordera M. Factors associated with bronchiectasis in patients with COPD. Chest 2011, 140:1130-1137. 10.1378/chest.10-1758, 21546440.
6. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000, 55:635-642. 10.1136/thorax.55.8.635, 1745831, 10899238.
7. Lebowitz MD, Burrows B. Quantitative relationships between cigarette smoking and chronic productive cough. Int J Epidemiol 1977, 6:107-113. 10.1093/ije/6.2.107, 892975.
8. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carre P, Perez T, Roche N. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009, 135:975-982. 10.1378/chest.08-2062, 19017866.
9. Riise GC, Ahlstedt S, Larsson S, Enander I, Jones I, Larsson P, Andersson B. Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid. Thorax 1995, 50:360-365. 10.1136/thx.50.4.360, 474276, 7785007.
10. Miravitlles M, Ferrer M, Pont A, Zalacain R, Varez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004, 59:387-395. 10.1136/thx.2003.008730, 1746989, 15115864.
11. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146:545-555. 10.7326/0003-4819-146-8-200704170-00152, 17310045.
12. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008, 3:331-350. 2629987, 18990961.
13. Blasi F, Mantero M, Aliberti S. Antibiotics as immunomodulant agents in COPD. Curr Opin Pharmacol 2012, 12:293-299. 10.1016/j.coph.2012.01.006, 22321568.
14. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010, 138:1202-1212. 10.1378/chest.10-0196, 21051396.
15. Miravitlles M, Marin A, Monso E, Vila S, de la RC, Hervas R, Esquinas C, Garcia M, Millares L, Morera J, Torres A. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J 2009, 34:1066-1071. 10.1183/09031936.00195608, 19386683.
16. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698. 10.1056/NEJMoa1104623, 3220999, 21864166.
17. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008, 178:1139-1147. 10.1164/rccm.200801-145OC, 18723437.
18. Blasi F, Bonardi D, Aliberti S, Tarsia P, Confalonieri M, Amir O, Carone M, Di MF, Centanni S, Guffanti E. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther 2010, 23:200-207. 10.1016/j.pupt.2009.12.002, 20025989.
19. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, Deng JM, MacNee W, Zhong XN. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 2010, 80:445-452. 10.1159/000321374, 20881376.
20. Suzuki T, Yanai M, Yamaya M, Satoh-Nakagawa T, Sekizawa K, Ishida S, Sasaki H. Erythromycin and common cold in COPD. Chest 2001, 120:730-733. 10.1378/chest.120.3.730, 11555501.
21. Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med 2005, 99:208-215. 10.1016/j.rmed.2004.06.009, 15715188.
22. Miravitlles M. Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir Med 2011, 105:1118-1128. 10.1016/j.rmed.2011.02.003, 21353517.
23. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003, 58:339-343. 10.1136/thorax.58.4.339, 1746649, 12668799.
24. Berkhof FF, Boom LN, ten Hertog NE, Uil SM, Kerstjens HA, van den Berg JW. The validity and precision of the Leicester Cough Questionnaire in COPD patients with chronic cough. Health Qual Life Outcomes 2012, 10:4. 10.1186/1477-7525-10-4, 3311606, 22230731.
25. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327. 10.1164/ajrccm/145.6.1321, 1595997.
26. Mahler DA, Mackowiak JI. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with COPD. Chest 1995, 107:1585-1589. 10.1378/chest.107.6.1585, 7781351.
27. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005, 2:75-79. 10.1081/COPD-200050513, 17136966.
28. Wyrwich KW, Fihn SD, Tierney WM, Kroenke K, Babu AN, Wolinsky FD. Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med 2003, 18:196-202. 10.1046/j.1525-1497.2003.20203.x, 1494834, 12648251.
29. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988, 26:724-735. 10.1097/00005650-198807000-00007, 3393032.
30. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000, 117:398S-401S. 10.1378/chest.117.5_suppl_2.398S, 10843984.
31. Voll-Aanerud M, Eagan TM, Wentzel-Larsen T, Gulsvik A, Bakke PS. Changes in respiratory symptoms and health-related quality of life. Chest 2007, 131:1890-1897. 10.1378/chest.06-2629, 17505046.
32. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012, 68:479-503. 10.1007/s00228-011-1161-x, 22105373.
33. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667. 10.1016/S0140-6736(12)60953-2, 22901887.
34. Andersen SW, Millen BA. On the practical application of mixed effects models for repeated measures to clinical trial data. Pharm Stat 2013, 12:7-16. 10.1002/pst.1548, 23239585.
35. Mallinckrodt CH, Kaiser CJ, Watkin JG, Molenberghs G, Carroll RJ. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin Trials 2004, 1:477-489. 10.1191/1740774504cn049oa, 16279288.
36. Kelsall A, Decalmer S, Webster D, Brown N, McGuinness K, Woodcock A, Smith J. How to quantify coughing: correlations with quality of life in chronic cough. Eur Respir J 2008, 32:175-179. 10.1183/09031936.00101307, 18287128.